Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: or equalequal togreater thanperipheralin subjects
  Phrases that lowered it: and safetysafety ofto investigateinvestigate thetype diabetes
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 5.5% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 71.5% (lowers risk) · Drug's FDA history
• Number of arms: 5 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 6906 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 15 (lowers risk) · Sponsor's track record
• Blinding: double (raises risk) · Design
• Drug's FAERS reports before start: 35282 (lowers risk) · Drug's FDA history
• Maximum age: not given (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain NCT02318706 · started 2015 · scored riskier than 8% of active trials completed
• Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy NCT01496365 · started 2011 · scored riskier than 33% of active trials completed
• A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y NCT01056315 · started 2009 · scored riskier than 22% of active trials terminated
• Study of DA-9801 to Treat Diabetic Neuropathic Pain NCT01813799 · started 2011 · scored riskier than 10% of active trials completed
• Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy NCT00857623 · started 2009 · scored riskier than 30% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.